Search

Your search keyword '"Mariani, Marianna"' showing total 19 results
Start Over Author "Mariani, Marianna"
19 results on '"Mariani, Marianna"'

4. Serum Inflamma-miR Signature: A Biomarker of Myelodysplastic Syndrome?

Author

Mariani, Marianna, primary, Mattiucci, Domenico, additional, Rossi, Elisa, additional, Mari, Valeria, additional, Masala, Erico, additional, Giuliani, Angelica, additional, Santini, Valeria, additional, Olivieri, Fabiola, additional, Marinelli Busilacchi, Elena, additional, Mancini, Stefania, additional, Olivieri, Attilio, additional, and Poloni, Antonella, additional

Published
2020
Full Text
View/download PDF

6. Severe COVID‐19 in a patient with chronic graft‐versus‐host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib

Author

Saraceni, Francesco, primary, Scortechini, Ilaria, additional, Mancini, Giorgia, additional, Mariani, Marianna, additional, Federici, Irene, additional, Gaetani, Mariana, additional, Barbatelli, Paolo, additional, Minnucci, Maria Luisa, additional, Bagnarelli, Patrizia, additional, and Olivieri, Attilio, additional

Published
2020
Full Text
View/download PDF

7. Structural Variations of Vaginal and Endometrial Microbiota: Hints on Female Infertility

Author

Riganelli, Lucia, primary, Iebba, Valerio, additional, Piccioni, Mariagrazia, additional, Illuminati, Isabella, additional, Bonfiglio, Giulia, additional, Neroni, Bruna, additional, Calvo, Ludovica, additional, Gagliardi, Antonella, additional, Levrero, Massimo, additional, Merlino, Lucia, additional, Mariani, Marianna, additional, Capri, Oriana, additional, Pietrangeli, Daniela, additional, Schippa, Serena, additional, and Guerrieri, Francesca, additional

Published
2020
Full Text
View/download PDF

10. Severe COVID‐19 in a patient with chronic graft‐versus‐host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib.

Author

Saraceni, Francesco, Scortechini, Ilaria, Mancini, Giorgia, Mariani, Marianna, Federici, Irene, Gaetani, Mariana, Barbatelli, Paolo, Minnucci, Maria Luisa, Bagnarelli, Patrizia, and Olivieri, Attilio

Subjects
HEMATOPOIETIC stem cells, STEM cell transplantation, COVID-19, HEMATOPOIETIC stem cell transplantation, CHRONICALLY ill, RUXOLITINIB
Abstract

Graft‐versus‐host disease (GVHD) is a common complication of hematopoietic stem cell transplant, which is known to be mediated by cytotoxic T‐cell effectors and dysregulated inflammatory cytokines. Similarly, the lung injury observed in severe COVID‐19 cases appears to be related to a massive production of pro‐inflammatory cytokines. The selective JAK1/2 inhibitor ruxolitinib has shown promising results in the context of GVHD, and different trials are currently underway in patients with severe COVID‐19; nevertheless, no clinical observation of safety or efficacy of treatment with ruxolitinib in this context has been published yet. We describe a first case of severe COVID‐19 developed after hematopoietic stem cell transplantation in a patient with a concomitant chronic GVHD (cGVHD), in which a treatment with ruxolitinib was administered with good tolerance and positive outcome. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

11. The exosomal surface phenotype and inflamma‐miR cargo correlate with MDS diagnosis.

Author

Cerisoli, Silvia, Marinelli Busilacchi, Elena, Mattiucci, Domenico, Rossi, Elisa, Mariani, Marianna, Guescini, Michele, Pugnaloni, Armanda, Olivieri, Fabiola, Olivieri, Attilio, and Poloni, Antonella

Subjects
ACUTE myeloid leukemia, VESICLES (Cytology)
Abstract

Keywords: exosomes; immunophenotype; inflamma-miRs; MDS biomarkers; miRNA; myelodysplastic syndromes EN exosomes immunophenotype inflamma-miRs MDS biomarkers miRNA myelodysplastic syndromes e4 e7 4 12/21/20 20210101 NES 210101 Myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal disorders characterised by peripheral cytopenia, dysplasia in one or more myeloid cell lineage, bone marrow failure, and an increased risk of developing acute myeloid leukaemia (AML). Their average diameter was 103 ± 18 nm in MDS patients, 114 ± 29 nm in AML patients, 102 ± 10 nm in CMML patients, and 110 ± 11 nm in controls. *P <= 0-05 **P <= 0-01. gl The inflamma-miRs identified in MDS patients appear to be involved in disease development and progression and could be reliable biomarkers of MDS development and predict the outcomes of individual patients. [Extracted from the article]

Published
2021
Full Text
View/download PDF

12. Successful Emergency Management of Uterine Scar Dehiscence and Placenta Percreta in 9-Gravida with Six Previous Caesarean Sections and an High Risk of Preterm Delivery

Author

Mariani Marianna, Merlino Lucia, Pecorini Francesco, Savone Delia, Piccioni Maria Grazia, Caccetta Jlenia, Riganelli Lucia, and Brunelli Roberto

Subjects
Pregnancy, medicine.medical_specialty, Hysterectomy, business.industry, Obstetrics, Placenta Percreta, medicine.medical_treatment, Myometrium, Emergency department, medicine.disease, Placenta previa, medicine.anatomical_structure, Placenta, medicine, Caesarean section, business, reproductive and urinary physiology
Abstract

Introduction: Placenta percreta is the development of an abnormal invasive placentation which potentially could develop an obstetrical emergency condition for the mother and fetus. Previous uterine surgery, as caesarean section, is the most significant factor contributing to its etiopathogenesis. Clinical Case Presentation: The present report describes a case of a 27-year-old with an obstetrical history of six previous caesarean sections presented at our Emergency Department, complaining sudden uterine constriction during the 32nd week of pregnancy with an ultrasonographical diagnosis of central placenta previa. Intervention: An emergency caesarean section was performed, but the absence of the uterine myometrium layer and the placenta (directly implanted on the uterine dehiscent scar) required a subsequent hysterectomy. The patient was not strictly monitored during the pregnancy, irregardless of her high risk of prenatal and perinatal complications. Conclusion: When evaluating women with a history of multiple previous caesarean sections, it is mandatory to evaluate the occurrence of the possible complications in order to treat and prevent life-threatening conditions for the mother and the new-born.

Published
2017

13. Age-related AMH decrease in ART patients

Author

Aragona, Cesare, Riganelli, Lucia, Franceschetti, Silvia, Caccetta, Jlenia, Mariani, Marianna, Vasselli, Ilaria, Micara, Giulietta, Linari, Antonella, and Salome Bezerra Espinola

Published
2017

14. Ultrasonography reappraisal of tubal patency in assisted reproduction technology patients: comparison between 2D and 3D-sonohysterosalpingography. A pilot study

Author

Riganelli, Lucia, primary, Casorelli, Assunta, additional, Caccetta, Jlenia, additional, Merlino, Lucia, additional, Mariani, Marianna, additional, Savone, Delia, additional, Carrone, Angela, additional, Franceschetti, Silvia, additional, Aragona, Cesare, additional, Pietrangeli, Daniela, additional, Aragona, Alessia, additional, Capri, Oriana, additional, and Piccioni, Maria G., additional

Published
2018
Full Text
View/download PDF

19. DNA demethylating therapy reverts mesenchymal stromal cells derived from high risk myelodysplastic patients to a normal phenotype.

Author

Maurizi, Giulia, Mattiucci, Domenico, Mariani, Marianna, Ciarlantini, Marco, Traini, Sabrina, Mancini, Stefania, Olivieri, Attilio, Leoni, Pietro, and Poloni, Antonella

Subjects
DNA, DNA demethylation, ACUTE myeloid leukemia, HEMATOPOIETIC stem cells, THERAPEUTICS
Abstract

The article discusses the effectiveness of DNA demethylating therapy as a treatment of the clonal stem cell disorder called myelodysplastic syndrome (MDS). The disease could lead to acute myeloid leukaemia (AML). Also cited are such topics as bone marrow (BM) lineages, haematopoietic stem cells (HSC), and mesenchymal stromal cells (MSC).

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results